Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

Juntaro Matsuzaki, Hidekazu Suzuki, Toshihiro Nishizawa, Kenro Hirata, Hitoshi Tsugawa, Yoshimasa Saito, Sawako Okada, Seiichiro Fukuhara, Toshifumi Hibi∥

Antimicrobial Agents and Chemotherapy · 2011 · 56 citations · 7 references

Concepts

Abstract

Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.

References

7